New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials

Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats

(2015) Cheng Liu et al.   BMC GASTROENTEROLOGY

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

(2015) J.T. Stefano et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

CD147 promotes liver fibrosis progression via VEGF-A/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells

(2015) Zhaoyong Yan et al.   CLINICAL SCIENCE

Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

(2014) Gamal E Shiha et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

(2014) Ikuo Nakamura et al.   PLoS One

The Effect of Antifibrotic Drugs in Rat Precision-Cut Fibrotic Liver Slices

(2014) Inge M. Westra et al.   PLoS One

Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases

(2013) Mohamed E. Shaker et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy

(2013) Roberto Iacovelli et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis

(2013) Syamantak Majumder et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

(2013) Bryan C. Fuchs et al.   HEPATOLOGY

Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats

(2013) Han-Chieh Lin et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

(2013) Carl-Henrik Heldin   Journal of Neuroimmune Pharmacology

Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat

(2013) Ying-Ying Yang et al.   LIVER INTERNATIONAL

Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs

(2013) Inge M. Westra et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Tyrosine kinase signaling in fibrotic disorders

(2012) Christian Beyer et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

(2012) C. J. Peer et al.   CLINICAL CANCER RESEARCH

Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis

(2012) Ching-Chih Chang et al.   CLINICAL SCIENCE

Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo

(2012) Feng Hong et al.   DIGESTIVE DISEASES AND SCIENCES

The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats

(2012) Shao-Jung Hsu et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Selective Internal Radiation Therapy of Hepatocellular Carcinoma: Potential Hepatopulmonary Shunt Reduction after Sorafenib Administration

(2012) Jens M. Theysohn et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study

(2011) M. Pinter et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pathogenesis of Liver Fibrosis

(2011) Virginia Hernandez-Gea et al.   Annual Review of Pathology-Mechanisms of Disease

Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis

(2011) Mohamed E. Shaker et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression

(2011) Mohamed E. Shaker et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis

(2011) Dominique Thabut et al.   HEPATOLOGY

Thyrosinkinaseinhibitoren in der Onkologie

(2011) T. Zander et al.   INTERNIST

Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice

(2011) Wen-Ling Kuo et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib

(2011) Yuqing Liu et al.   JOURNAL OF HEPATOLOGY

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

(2011) Romain Coriat et al.   PLoS One

Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis

(2011) Mohamed E. Shaker et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice

(2011) Dina S. El-Agamy et al.   INFLAMMOPHARMACOLOGY

Receptor Tyrosine Kinase Coactivation Networks in Cancer

(2010) A. M. Xu et al.   CANCER RESEARCH

Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors

(2010) Vanessa Almendro et al.   CURRENT DRUG TARGETS

Antiangiogenic therapies in portal hypertension: A breakthrough in hepatology

(2010) O. Rosmorduc   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?

(2010) Dominique Thabut et al.   JOURNAL OF HEPATOLOGY

New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis

(2010) Yan Wang et al.   JOURNAL OF HEPATOLOGY

Targeting non-malignant disorders with tyrosine kinase inhibitors

(2010) Friedrich Grimminger et al.   NATURE REVIEWS DRUG DISCOVERY

Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media

(2010) MINORU TOMIZAWA et al.   Experimental and Therapeutic Medicine

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

(2009) M Hennenberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258

(2009) Yuqing Liu et al.   LABORATORY INVESTIGATION

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

(2009) Onder Tonyali et al.   MEDICAL ONCOLOGY

Liver Transplantation: The Current Situation

(2009) Rene Adam et al.   SEMINARS IN LIVER DISEASE

Acute Hepatitis in a Patient With Cirrhosis and Hepatocellular Carcinoma Treated With Sorafenib

(2008) Lucia Llanos et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Sorafenib-Induced Liver Failure

(2008)   AMERICAN JOURNAL OF GASTROENTEROLOGY

Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors

(2008) Jochen Rossler et al.   CURRENT CANCER DRUG TARGETS

Mechanisms of Hepatic Fibrogenesis

(2008) Scott L. Friedman   GASTROENTEROLOGY

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

(2008) Marc Mejias et al.   HEPATOLOGY

PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling

(2008) Yuqing Liu et al.   LABORATORY INVESTIGATION